In the primary analysis of seven trials, PCSK9 inhibitors therapy did not significantly reduce the risk of cardiac arrest (RR 1.20, 95%CI 0.61–2.33; P = 0.60; I2 = 0%; Fig 6). The gene discussed is PCSK9; the disease is cardiac arrest.